Discovery of 1-methyl-1 H-imidazole derivatives as potent Jak2 inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 1, 2014, Pages 144-158

  Su, Qibin ^a   Ioannidis, Stephanos ^a   Chuaqui, Claudio ^a   Almeida, Lynsie ^a   Alimzhanov, Marat ^a   Bebernitz, Geraldine ^a   Bell, Kirsten ^a   Block, Michael ^a   Howard, Tina ^b   Huang, Shan ^a   Huszar, Dennis ^a   Read, Jon A ^b   Rivard Costa, Caroline ^a   Shi, Jie ^a   Su, Mei ^a   Ye, Minwei ^a   Zinda, Michael ^a  

^a ASTRAZENECA   (United Kingdom)

^b AstraZeneca   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 1H IMIDAZOLE 4 AMINE; 1 METHYL 1H IMIDAZOLE DERIVATIVE; 2 CHLORO 6 FLUORO N (1 METHYL 1H IMIDAZOL 4 YL)PYRIDO[2,3D ]PYRIMIDIN 4 AMINE; 2 CHLORO 6 METHOXY N (1 METHYL 1H IMIDAZOL 4 YL)QUINAZOLIN 4 AMINE; 2 CHLORO N (1 METHYL 1H IMIDAZOL 4 YL)PYRIDO[3,4D ]PYRIMIDIN 4 AMINE; 2 CHLORO N (1 METHYL 1H IMIDAZOL 4 YL)QUINAZOLIN 4 AMINE; 2,4 DICHLORO 6 METHOXYQUINAZOLINE; 2,7 DICHLORO N (1 METHYL 1H IMIDAZOL 4 YL)PYRIDO[2,3 D]PYRIMIDIN 4 AMINE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; IMIDAZOLE DERIVATIVE; JANUS KINASE 2 INHIBITOR; STAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL FUNCTION; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT; X RAY; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; DRUG DISCOVERY; HUMANS; IMIDAZOLES; JANUS KINASE 2; MICE; PROTEIN KINASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892586858     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401546n     Document Type: Article

References (42)

1. Quintas-Cardama, A.; Vertovsek, S. New JAK2 inhibitors for myeloproliferative neoplasms Expert Opin. Invest. Drugs 2011, 20, 961-972
2. Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.; Huntly, B. J. P.; Boggon, T. J.; Wlodarska, I.; Clark, J. J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Frohling, S.; Deohner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R. A.; Tefferi, A.; Griffin, J. D.; Eck, M. J.; Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland, D. G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 2005, 7, 387-397
3. Anand, S.; Huntly, B. Disordered signaling in myeloproliferative neoplasms Hematol. Oncol. Clin. North Am. 2012, 26, 1017-1035
4. Baxter, E. J.; Scott, L. M.; Campbell, P.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 2005, 365, 1054-1061
5. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garc-on, L.; Raslova, H.; Berger, R.; Bennacaur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 2005, 434, 1144-1148
6. Passamonti, F.; Cervantes, F.; Vannucchi, A. M.; Morra, E.; Rumi, E.; Pereira, A.; Guglielmelli, P.; Pungolino, E.; Caramella, M.; Maffioli, M.; Pascutto, C.; Lazzarino, M.; Cazzola, M.; Tefferi, A. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood 2010, 115, 1703-1708
7. Kiss, R.; Sayeski, P. P.; Keseru, G. M. Recent developments on JAK2 inhibitors: a patent review Expert Opin. Ther. Pat. 2010, 20, 471-495
8. Lucia, E.; Recchia, A. G.; Gentile, M.; Bossio, S.; Vigna, E.; Mazzone, C.; Madeo, A.; Morabito, L.; Gigliotti, V.; deStefano, L.; Caruso, N.; Servillo, P.; Franzese, S.; Bisconte, M. G.; Gentile, C.; Morabito, F. Janus kinase 2 inhibitors in myeloproliferative disorders Expert Opin. Invest. Drugs 2011, 20, 41-59 and the references cited therein.
9. Verstovsek, S.; Kantarjian, H.; Mesa, R. A.; Pardanani, A. D.; Cortes-Franco, J.; Thomas, D. A.; Estrov, Z.; Fridman, J. S.; Bradley, E. C.; Erickson-Viitanen, S.; Vaddi, K.; Levy, R.; Tefferi, A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N. Engl. J. Med. 2010, 363, 1117-1127
10. Lasho, T. L.; Tefferi, A.; Hood, J. D.; Verstovsek, S.; Gilliland, D. G.; Pardanani, A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW51 or JAK2 exon 12 mutations as well as mutation negative patients Leukemia 2008, 22, 1790-1792
11. Santos, F. P.; Kantarjian, H. M.; Jain, N.; Manshouri, T.; Thomas, D. A.; Garcia-Manero, G.; Kennedy, D.; Estrov, Z.; Cortes, J.; Verstovsek, S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera essential thrombocythemia myelofibrosis Blood 2010, 115, 1131-1136
12. Tyner, J. W.; Bumm, T. G.; Deininger, J.; Wood, L.; Aichberger, K. J.; Loriaux, M. M.; Druker, B. J.; Burns, C. J.; Fantino, E.; Deininger, M. W. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms Blood 2010, 115, 5232-5240
13. Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies Leukemia 2011, 25, 1751-1759
14. Ma, L.; Zhao, B.; Walgren, R.; Clayton, J. A.; Blosser, W. D.; Burkholder, T. P.; Smith, M. C. Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models Ann. Meet. Abstr. 2010, 116, 4087
15. Purandare, A. V.; McDevitt, T. M.; Wan, H.; You, D.; Penhallow, B.; Han, X.; Vuppugalla, R.; Zhang, Y.; Ruepp, S.; Trainor, G. L.; Lombardo, L.; Pedicord, D.; Gottardis, M. M.; Ross-Macdonald, P.; de Silva, H.; Hosbach, J.; Emanuel, S. L.; Blat, Y.; Fitzpatrick, E.; Taylor, T. L.; McIntyre, K. W.; Michaud, E.; Mulligan, C.; Lee, F. Y.; Woolfson, A.; Lasho, T. L.; Pardanani, A.; Tefferi, A.; Lorenzi, M. V. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2 Leukemia 2012, 26, 280-288
16. Tam, C. S.; Verstovsek, S. Investigational Janus kinase inhibitors Expert Opin. Invest. Drugs 2013, 687-699 and the references cited therein.
17. Ioannidis, S.; Lamb, M. L.; Davies, A. M.; Almeida, L.; Su, M.; Bebernitz, G.; Ye, M.; Bell, K.; Alimzhanov, M.; Zinda, M. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6524-6528
18. Ioannidis, S.; Lamb, M. L.; Almeida, L.; Guan, H.; Peng, B.; Bebernitz, G.; Bell, K.; Alimzhanov, M.; Zinda, M. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: discovery of potent and selective JAK2 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1669-1673
19. Wang, T.; Ioannidis, S.; Almeida, L.; Block, M. H.; Davies, A. M.; Lamb, M. L.; Scott, D. A.; Su, M.; Zhang, H.-J.; Alimzhanov, M.; Bebernitz, G.; Bell, K.; Zinda, M. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3- carbonitriles as JAK2 kinase inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2958-2961
20. Guan, H.; Lamb, M.; Peng, B.; Huang, S.; DeGrace, N.; Read, J.; Hussain, S.; Wu, J.; Rivard, C.; Alimzhanov, M.; Bebernitz, G.; Bell, K.; Ye, M.; Zinda, M.; Ioannidis, S. Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target Bioorg. Med. Chem. Lett. 2013, 23, 3105-3110
21. Ioannidis, S.; Lamb, M. L.; Wang, T.; Almeida, L.; Block, M. H.; Davies, A. M.; Peng, B.; Su, M.; Zhang, H.-J.; Hoffmann, E.; Rivard, C.; Green, I.; Howard, T.; Pollard, H.; Read, J.; Alimzhanov, M.; Bebernitz, G.; Bell, K.; Ye, M.; Huszar, D.; Zinda, M. Discovery of 5-chloro- N 2-[(1 S)-1-(5- fluoropyrimidin-2-yl)ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4- diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway J. Med. Chem. 2011, 54, 262-276
22. Hedvat, M.; Huszar, D.; Herrmann, A.; Gozgit, J. M.; Schroeder, A.; Sheehy, A.; Buettner, R.; Proia, D.; Kowolik, C. M.; Xin, H.; Armstrong, B.; Bebernitz, G.; Weng, S.; Wang, L.; Ye, M.; McEachern, K.; Chen, H.; Morosini, D.; Bell, K.; Alimzhanov, M.; Ioannidis, S.; McCoon, P.; Cao, Z. A.; Yu, H.; Jove, R.; Zinda, M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors Cancer Cell 2009, 16, 487-497
23. Gozgit, J. M.; Bebernitz, G.; Patil, P.; Ye, M.; Wu, J.; Su, N.; Wang, T.; Ioannidis, S.; Davies, A. M.; Huszar, D.; Zinda, M. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2 J. Biol. Chem. 2008, 283, 32334-32343
24. Gompper, R.; Junius, M.; Wagner, H. U. 2,4,5-Tris(diethylamino)-4 H -imidazole and derived fulvenes and fulvalene Tetrahedron Lett. 1981, 31, 2973-2976
25. Wang, T.; Lamb, M. L.; Scott, D. A.; Wang, H.; Block, M. H.; Lyne, P. D.; Lee, J. W.; Davies, A. M.; Zhang, H-J; Zhu, Y.; Gu, F.; Han, Y.; Wang, B.; Mohr, P. J.; Kaus, R. J; Josey, J. A.; Hoffmann, E.; Thress, K.; MacIntyre, T.; Wang, H.; Omer, C. A.; Yu, D. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases J. Med. Chem. 2008, 51, 4672-4684
26. Compound 28 was prepared using the procedure described in: Almeida, L.; Chuaqui, C. E.; Ioannidis, S.; Peng, B.; Su, M. Preparation of 2,4-diamino-1,3,5-triazine derivatives as JAK inhibitors. PCT Int. Appl. WO 2009150462 A1 20091217, 2009.
27. Pierce, A. C.; Sandretto, K. L.; Bemis, G. W. Kinase inhibitors and the case for CH···O hydrogen bonds in protein-ligand binding Proteins 2002, 49, 567-576
28. Beattie, J. F.; Breault, G. A.; Ellston, R. P.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimization of substituted 4,6-bis anilino pyrimidines Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960
29. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007, 11, 217-227
30. Glide, version 4.5; Schrodinger, LLC: New York, 2010.
31. Lyne, P. D.; Lamb, M. L.; Saeh, J. C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring J. Med. Chem. 2006, 49, 4805-4808
32. Gutiérrez-de-Terán, H.; Aqvist, J. Linear interaction energy: method and applications in drug design Methods Mol. Biol. 2012, 819, 305-323
33. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
34. For assay conditions and experimental details: Dowling, J. E.; Alimzhanov, M.; Bao, L.; Block, M. H.; Chuaqui, C.; Cooke, E. L.; Denz, C. R; Hird, A.; Huang, S.; Larsen, N. A.; Peng, B.; Pontz, T. W.; Rivard-Costa, C.; Saeh, J. C; Thakur, K.; Ye, Q.; Zhang, T.; Lyne, P. D. Structure and property based design of pyrazolo[1,5- a ]pyrimidine inhibitors of CK2 kinase with activity in vivo ACS Med. Chem. Lett. 2013, 4, 800-805
35. Quentmeier, H.; MacLeod, R. A.; Zaborski, M.; Drexler, H. G. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders Leukemia 2006, 20, 471-476
36. Giovanella, B. C.; Stehlin, J. S. Heterotransplantation of human malignant tumors in "nude" thymusless mice. I. Breeding and maintenance of "nude" mice. J Natl Cancer Inst. 1973, 51, 615-619. The nude mice were obtained from Taconic: http://www.taconic.com/wmspage.cfm?parm1= 873.
37. Bosma, G. C.; Custer, R. P.; Bosma, M. J. A severe combined immunodeficiency mutation in the mouse Nature 1983, 301, 527-530
38. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002; http://www.pymol.org.
39. The CCP4 suite: programs for protein crystallography. Collaborative Computational Project, Number 4. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, D50, 760-763.
40. Coot; Emsley, P.; Cowtan, K. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126
41. Refmac5: Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
42. Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version 2.11.5; Global Phasing Ltd: Cambridge, United Kingdom, 2011.